Pre-eclampsia: its pathogenesis and pathophysiology
P Gathiram, J Moodley

Abstract
Pre-eclampsia is a pregnancy-specific disorder that has a worldwide prevalence of about 5–8%. It is one of the main causes of maternal and perinatal mortality and morbidity globally and accounts for 50 000–60 000 deaths annually, with a predominance in the low- and middle-income countries. It is a multisystemic disorder however its aetiology, pathogenesis and pathophysiology are poorly understood. Recently it has been postulated that it is a two-stage disease with an imbalance between angiogenic and anti-angiogenic factors. This review covers the latest thoughts on the pathogenesis and pathology of pre-eclampsia. The central hypothesis is that pre-eclampsia results from defective spiral artery remodelling, leading to cellular ischaemia in the placenta, which in turn results in an imbalance between anti-angiogenic and pro-angiogenic factors. This imbalance in favour of anti-angiogenic factors leads to widespread endothelial dysfunction, affecting all the maternal organ systems. In addition, there is foetal growth restriction (FGR). The exact aetiology remains elusive.

Keywords: pre-eclampsia, major cause of maternal mortality and morbidity, placenta

Submitted 6/7/15, accepted 17/2/16
Cardiovasc J Afr 2016; 27: 71–78 www.cvja.co.za
DOI: 10.5830/CVJA-2016-009

Pre-eclampsia (PE) is a disorder of pregnancy with a worldwide prevalence of about 5–8%. It is characterised by new-onset hypertension with systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg, measured on two occasions at least four hours apart, and proteinuria of > 0.3 g per 24 hours or ≥ 1+ proteinuria, detected by urine dipstick after 20 weeks of pregnancy, or in the absence of proteinuria, new-onset hypertension with onset of any one of the following: thrombocytopenia (platelet count < 100 000/μl), renal insufficiency (serum creatinine concentration > 1.1 mmol/l or a doubling of the serum creatinine concentration in the absence of other renal disease), impaired liver function (raised concentrations of liver transaminases to twice normal concentrations), pulmonary oedema, or cerebral or visual problems. PE is one of the main causes of maternal mortality, resulting in about 50 000–60 000 deaths annually worldwide. In addition, it is associated with an increased risk of the mother and her child developing cardiovascular complications and diabetes mellitus later in life. Furthermore, PE is a multi-systemic syndrome, involving genetic and environmental factors in its pathogenesis and pathophysiology and the only known treatment is delivery of the foetus and placenta.

In addition, there are subtypes of PE, which are based on the time of onset or recognition of the disease. It is generally divided into two main types, early- and late-onset PE. The latter comprises the majority (> 80%) of pre-eclamptics. In the early-onset type, the clinical signs appear before 33 gestational weeks, while in the late-onset type they occur at and after 34 weeks. However, it is the early-onset type that is responsible for most of the high maternal and foetal mortality and morbidity rates.

The main pathological feature of early-onset PE is incomplete transformation of the spiral arteries, resulting in hypoperfusion of the placenta and reduced nutrient supply to the foetus. This results in signs of foetal growth restriction (FGR). On the other hand, in late-onset type, the spiral arteries, if at all, are slightly altered in diameter and there are no signs of FGR. This is because early-onset pre-eclampsia is related to placental hypoperfusion, while in the late-onset type there is either no change or a shallow modification of the spiral arteries, leading in some cases to hyperperfusion of the placenta. Therefore, it seems that early- and late-onset PE have different pathophysiological and aetiological pathways.

In normal pregnancy, the extracellular fluid and plasma volumes increase by 30–50% and 30–40%, respectively, perhaps due to a decrease in systemic vascular resistance and increase in cardiac output. The decreased systemic vascular resistance is thought to be due the presence of nitric oxide. In early-onset PE, there is a decrease in plasma volume, occurring at 14–17 gestational weeks, before the clinical onset of the disorder. This aspect is discussed more fully later under the role of the renin–angiotensin–aldosterone system (RAAS).

Despite decades of research, the pathogenesis and pathophysiology of PE are still poorly or incompletely understood. The pathogenic process of PE begins during the first trimester, long before clinical signs are apparent. Hence it is difficult to identify early biomarkers. The main reason for this is perhaps ethical in nature, as it is difficult to conduct studies in early pregnancies, as these may compromise both the mother...
and child, and furthermore the pathogenic processes could be multifactorial. In any event, it is generally felt that lack of adequate placental development is the root cause of early-onset PE because the only known treatment of the disorder is delivery of the foetus and placenta. It is, however, essential to understand the features of placental development in normal pregnancies in order to understand the pathophysiology of PE.

Role of the placenta in normal pregnancies

Placental and trophoblast invasion of the maternal tissue involves two processes, firstly vascularisation to establish a foeto-placental vascular network, and secondly, invasion of the maternal spiral arteries by the cytотrophoblasts or endovascular trophoblasts (EVTs). At the time of implantation, trophoblastic cells differentiate into cytотrophoblasts and syncytiotrophoblasts. The cytотrophoblasts form the extravillous trophoblasts (EVT), which invade the decidual and junctional zone myometrial segments, the inner third of the myometrium and the spiral arteries. The EVT induce remodelling of the latter, perhaps by causing loss of the elastic lamina, most of the smooth muscle cells, and temporarily replacing the endothelial cells, thus transforming a high-resistance, low-flow vascular system into a low-resistance, high-flow type, essential for normal foetal growth.

Therefore, the cytотrophoblasts, epithelial in nature, replace the endothelial cells and in the process, the epithelial-like receptors are replaced with maternal adhesion molecules such as vascular endothelial (VE) cadherin vascular adhesion molecule-1, platelet-endothelial molecule-1, and αVEβ3 integrin. This perhaps accounts for the prevention of foetal rejection. The trophoblasts therefore take on the phenotype of endothelial cells and are in direct contact with maternal blood, but the maternal and foetal blood do not mix.

The syncytiotrophoblasts are multinucleated, line the chorionic villi, and act as an interface between maternal and foetal blood. However, according to Brosens et al. (2011), trophoblast invasion of the spiral arteries is preceded by oedema of the vessel wall, disintegration of the elastic fibres and changes in the smooth muscle layer, leading to a loss of myofibris. Hence it is not the generally believed concept that the trophoblastic cells themselves cause disintegration of the elastic fibres and loss of myofibris. In addition, development of the foetus initially occurs under low oxygen tension and placental perfusion is only from the intervillous space, and unplugging of the maternal spiral arteries occurs at about the 12th gestational week.

The migration of trophoblasts into the spiral arteries is influenced by a number of factors such as cytokines, growth factors, oxygen tension, and the local cellular environment, for example immune cells such as macrophages and decidual/uterine natural killer (dNK) cells. The dNK cells are thought to play an important role in regulating placentaion but the exact mechanism of action is still unclear.

Systemic inflammatory response in normal pregnancies

The foetal trophoblast is regarded as an allo-antigen and the mother reacts to this and mounts a sterile, low-grade systemic inflammatory response. It is thought that syncytiotrophoblast microparticles (STMBs) detected in the maternal circulation could be the cause. However, it is known that utero-foetal perfusion only begins towards the end of the first trimester, while increased levels of STMBs in the maternal circulation are detected during the second and third trimesters. The initial inflammatory response during the first trimester could be due to an interaction between the decidual immune cells and trophoblast cells, and that a secondary inflammatory response during the second and third trimester could be due to syncytiotrophoblast microparticles released into the mother's vascular system.

Placental blood flow in pre eclampsia and its consequences

In PE, it has almost been established that there is reduced blood flow to the placenta, especially in the early-onset type, because of defective spiral artery remodelling and acute arterosclerosis. In vivo techniques (magnetic resonance imaging and Doppler low-flow measurements) have confirmed this in early- but not late-onset PE.

In PE the defects in spiral artery remodelling are restricted to the distal segments of the spiral arteries, that is the proximal decidua and the junctional zone (JZ) myometrial segments, and hence the myometrial spiral arteries still have much of their smooth muscle cells and elastic lamina, with absent or partial transformation of the arteries in the JZ myometrial segment.

The exact mechanism for this is not known but various factors, such as abnormal genetic variations, biology of the trophoblasts or defective trophoblast differentiation acting together with extrinsic factors, such as maternal constitutional factors, action of macrophage defense mechanisms, impaired action of dNK cells and maternal endothelial cells have been advanced. Recently, it has been proposed that proteolytic activity of the different populations of the EVTs could be involved in invasion of the decidua and spiral arteries.

Studies conducted in our laboratories showed that a PE-like syndrome can be produced in a rat model by reducing the placental blood flow through the administration of nitro-L-arginine methyl ester (L-NAME). In addition, co-administration of sildenafl citrate, which blocks the action of L-NAME, prevented the PE-like syndrome. Furthermore, we have shown that once the administration of L-NAME is discontinued, the pathophysiology of PE continues until birth of the pups, and thereafter the high blood pressure and proteinuria return to almost normal levels.

The question then arises as to what the effects of the reduced placental blood flow or hypoperfusion on the maternal syndrome, namely hypertension, proteinuria and oedema, are. Is it the reduced blood flow per se that triggers events leading to the maternal syndrome, or is it some other factors associated with ischaemia?

It is believed that reduced placental blood flow could result in hypoxia of the placenta, which has been suggested as the ultimate cause of PE. However, no in vivo measurements of oxygen tension in the intervillous space have been made to claim that hypoxia does occur. Nevertheless, it is believed that that reduced blood flow or chronic hypoxia on their own are not the direct cause of the placental lesions seen in PE but could be a contributing factor. It has therefore been assumed that
the lesions could rather be due to an ischaemia-reperfusion or hypoxia-reoxygenation (HR) type of injury caused by free radicals such as reactive oxygen species (ROS).10

Furthermore, it has been speculated that an intermittent type of blood flow occurs in the intervillous space, which could be responsible for the HR type of injury.11 To support this, Yung et al. in 201412 showed that high levels of activation of unfolded protein-response pathways due to HR damage to the endoplasmic reticulum occurred in placental samples taken from early- but not late-onset PE. Accumulation of aggregates of unfolded protein response (UPR) or misfolded proteins has been observed in PE placentas and it is believed that these may contribute to the pathophysiology of the disorder.13 However, no measurements have been made to show that blood flow to the intervillous space is indeed intermittent. We believe that it is the pulsatile nature of blood flow from the spiral arteries that could contribute to the pathophysiology of the disorder.13 However, no measurements have been made to show that blood flow to the intervillous space is indeed intermittent. We believe that it is the pulsatile nature of blood flow from the spiral arteries that could be responsible for the HR type of injury.11

The HR damage to the placenta, however, results in increased stress of the syncytiotrophoblasts, causing necrosis, apoptosis and release of excess placental debris (STMBs and vesicles), compared to a normal pregnancy, into the maternal circulation.14 In addition, soluble endoglin (sEng) is the extracellular component of Eng, which is highly expressed in the syncytiotrophoblasts, and shedding of STMBs causes either mechanical disruption or proteolytic cleavage of sEng, and excess amounts of it are present in PE. The details of this are discussed later in this review.

It is therefore believed that placental ischaemia-reperfusion injury is central to the development of PE. In addition to STMBs, pro-inflammatory cytokines, responsible for endothelial dysfunction and increased inflammatory responses, lead to the clinical signs of PE, such as hypertension, proteinuria and thrombotic micro-angiopathy, presenting as haemolysis, elevated liver enzymes and low platelet count (HELLP) syndrome, pulmonary or cerebral oedema and seizures.15,16 However, there is no clear evidence that this really occurs and it has not been conclusively proven that STMB vesicles, and micro- and nanoparticle levels are significantly raised in PE compared to normal pregnancies, and that these substances give rise to the inflammatory disorder seen in PE.

**Pro-angiogenic and anti-angiogenic factors in pre-eclampsia**

**Pro-angiogenic factors, VEGF, PI GF and TGF-β**

Vascular endothelial growth factor (VEGF) and platelet growth factor (PGF) play a key role in placental angiogenesis and are believed to be secreted by trophoblast cells. VEGF is thought to be essential for integrity of the maternal endothelial cells.17 Both elevated and reduced levels of VEGF in the maternal circulation have been reported in PE.18 These conflicting results could be due to the methodologies used. Elevated levels could perhaps be due to the use of commercial kits that measure both the bound and the soluble forms of VEGF in the maternal circulation.

A longitudinal study showed that serum PI GF concentrations increased from 15–19 pg/ml through to 21–25 gestational weeks, and peaked at 27–30 weeks in uncomplicated pregnancies, in women with small-for-gestational-age (SGA) neonates and PE without SGA neonates, and thereafter the levels declined towards 35–36 gestational weeks.19 However, in PE complicated by SGA, the peak occurred at 21–25 gestational weeks, but at all times the levels were lower than in women with PE only.20

The transforming growth factor-β (TGF-β) family, especially TGF-β1 and TGF-β3, have also been implicated in pre-eclampsia,21–25 but their exact mechanism of action is not known except to say that they are expressed in the pre-eclamptic placenta and reduce trophoblast proliferation, migration and invasion.22

**Anti-angiogenic factors sFlt-1 and sEng**

The antiangiogenic factors are VEGF receptors (VEGFR1 and VEGFR2) and Eng. VEGFR1 is also known as fms-like tyrosine kinase-1 (Flt-1), which is membrane bound, while VEGFR2 is known as kinase insert domain receptor (KDR).26,27 It is known that sFlt-1, a splice variant of Flt-1, is the free form found in the circulation.28 Soluble Eng has anti-angiogenic effects, and as it has binding sites for TGF-β1 and β3, it is thought to play a role in PE.29

Venkatesha et al. found that Eng mRNA expression was significantly up-regulated in placental tissue (obtained at delivery), particularly in syncytiotrophoblasts in PE at 25 and 40 gestational weeks compared to age-matched control pregnancies.30 These researchers also found that this was accompanied by a significant rise in sera levels (obtained before delivery) of sEng in PE women compared to control pregnancies, and concluded that both sEng and sFlt-1 could be blocking the actions of TGF-β1 and VEGF, respectively. However, no significant differences in serum TGF-β1 levels were detected between normal-pregnancy and PE women.31

Venkatesha et al. further showed that administration of sEng to pregnant rats significantly increased the mean arterial pressure at 17–18 days of pregnancy but it had mild to modest effects on proteinuria. However, co-administration of sFlt-1 caused high levels of proteinuria, hypertension and evidence of the HELLP syndrome.32

**Imbalance in angiogenic and anti-angiogenic state in PE**

There is increasing evidence that suggests an imbalance between pro-angiogenic and anti-angiogenic factors are responsible for the pathophysiological effects seen in PE,33,34 and these appear before clinical signs are apparent.35 However, it is not exactly known why some women develop PE while others with similar features, such as placental ischaemia and endothelial dysfunction, give birth only to SGA neonates without classical clinical signs of the disorder.36

Serum samples taken at the time of delivery have shown significantly increased sFlt-1 and decreased VEGF and PLGF concentrations in PE, compared to normotensive controls.37 In vitro studies showed that serum from PE inhibited tube formation in human umbilical vein endothelial cell (HUVEC) lines compared to that from controls, and administration of adenovirus expressing sFlt-1 to pregnant rats caused hypertension, albuminuria and glomerular endotheliosis, similar to that observed in PE.38
Cross-sectional studies conducted in our laboratories among black African women at term before delivery demonstrated that variations in plasma levels of pro-angiogenic (PIGF and TGF-β) and anti-angiogenic (sEng and sFlt-1) factors indicated an association with PE. In a similar study, we observed that serum sFlt-1 concentrations were significantly raised in early-onset PE and higher in late-onset PE compared to normotensive controls and chronic hypertensives, while VEGF was not detectable in all groups. A longitudinal study showed that patients with SGA neonates had significantly higher plasma sEng concentrations throughout their pregnancies, but in those who developed early- and late-onset PE, the levels were significantly higher at 23 and 30 gestational weeks, respectively, compared to normal pregnancies. In the case of plasma sFlt-1 levels, early- and late-onset PE had higher levels at 26 and 29 gestational weeks, respectively, compared to normal pregnancies. However, those with both early- and late-onset PE and those with SGA neonates had lower levels of PIGF throughout pregnancy, compared to controls. Other studies show similar findings.

In addition, it was reported that plasma sFlt-1 levels were elevated in pre-eclampsia compared to normal pregnancies at 6–10 weeks and more so at 2–5 weeks prior to the development of a clinical diagnosis. A pilot study showed that extracorporeal removal of 17–34% of sFlt-1 from pre-eclamptic women between gestational ages 27 and 31 weeks lowered the blood pressure and reduced proteinuria and other complications.

The disproportionate levels of anti-angiogenic factors such as sEng and sFlt-1, and pro-angiogenic factors such as VEGF, PIGF and TGFβ, are believed to cause generalised maternal endothelial dysfunctions, leading to hypertension, renal endotheliosis and blood coagulation.

Immune factors and inflammation, cytokines and chemokines

There is increasing evidence suggesting that both innate and adaptive immune processes are involved in the pathogenesis of PE. Predominance of Th1 immunity is not only related to poor placentalation but also to the exaggerated inflammatory response and endothelial dysfunction seen in PE.

In a recent study it was shown that between 14 and 18 gestational weeks, serum tumour necrosis factor-α (TNF-α), interleukin 10 (IL-10) and interferon-γ (INF-γ) levels were significantly lower in PE than in normal pregnancy. In another study, it was shown that serum levels of circulating cytokines, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p40, IL-12p70, IL-18, INF-γ, TNF-α and chemokine interferon-γ-inducible protein (IP-10), monocyte chemotactic protein-1 (MCP-1) and adhesion molecules [intercellular adhesion molecule (ICAM-1) and vascular cell adhesion molecule (VCAM-1)] were raised in PE compared to controls.

In early-onset PE, the plasma TNF-α and its receptors TNFR1, IL-1β and IL-12 levels, and heat shock protein-70 (Hsp-70) were significantly higher than in late-onset PE, while IL-10 concentrations were higher in late-onset than early-onset PE. Controversial findings have therefore been reported in the levels of some of the cytokines. The differences noted could have been due to the time of taking blood samples. For example, in the study by Kumar et al., the samples were taken between 14 and 18 gestational weeks because 24 hours before delivery, raised levels of IL-4 and TNF-α were found, while the levels of INF-γ were not significantly different between those with PE and controls. However, it is believed that in PE compared to normal pregnancy, there is a shift to Th-1 type from Th-2 type of immunity. It is known that Th-1 type produces INF-γ and TNF-α, and hence it would be expected that the latter cytokines would be raised in the circulation.

A meta-analysis and a systematic review of published articles on concentrations of TNF-α, IL-6 and IL-10 in the maternal circulation showed that the concentrations were significantly higher in PE compared to controls. It is noteworthy that in one study in which TNF-α levels were measured, there was also no significant difference between PE patients and controls. From these data, Lau et al. concluded that in the third trimester, PE is associated with higher levels of TNF-α, IL-6 and IL-10 in the maternal circulation, compared to normal pregnancies, but they found insufficient evidence to state that this was so in the first and second trimesters as well.

A recent study conducted at a mean gestational age of 34 weeks demonstrated that plasma IL-6, IL-8 and INF-γ levels were significantly higher in PE compared to age-matched normal pregnant and non-pregnant women. The level of TNF-α was not significantly different but the level of IL-10 was significantly higher in normotensives than pre-eclamptics. In addition, it was found that severe PE was associated with increased plasma levels of IL-8, IL-6, TNF-α, IL-12 and INF-γ, linking these cytokines with the exaggerated inflammatory response in this condition.

Studies from our laboratories have just recently shown that blood levels of Th-1 (TNF-α, IL-2, IL-12p70), INF-γ and granulocyte-macrophage colony-stimulating factor (GM-CSF), and Th-2 (IL-4, IL-5, IL-10 and IL-13) cytokines are similar in PE and normotensive pregnant women.

Low oxygen tension, oxidative stress in gene expression levels in PE

In early-onset PE, oxidative stress caused by low oxygen tension or by disruption of the oxygen-sensing mechanism in placentas is believed to cause over-expression of hypoxia inducible factor-1 (HIF-1α) in placental tissue, and also to the release of increased levels into the circulation. In normal pregnancy, placental expression and formation of HIF-1α increased in a hypoxic environment during the first trimester and this was paralleled by TGF-β, of which early trophoblast differentiation and placental expression of both molecules remained high until about the 10th gestational week when placental O2 levels began to increase. This was speculated to be responsible for extravillous trophoblast (EVT) outgrowth and invasion of the spiral arteries. However, it was noted that in PE the expression and formation of HIF-1α and consequently TGF-β remained high, resulting in shallow trophoblast invasion of the spiral arteries. These findings were confirmed by other researchers.

Increased expression of the haeme (Hb) gene in the presence of hypoxia or oxidative stress has also been noted in PE placentas, and together with foetal haemoglobin (HbF), is thought to be involved in the pathogenesis of PE. In a review article, Hansson et al. in 2014 showed that free Hb, in addition to causing oxidative stress, also caused placental and kidney damage.
Placental hypoxia and perhaps oxidative stress, which occurs in PE, is also known to upregulate the gene expression and formation of Eng in placental tissue, perhaps via TGF-β. The action of Eng and its receptor sEng have already been discussed. Perhaps in a similar manner, there is over-expression of genes responsible for the formation of sFlt-1, PlGF and VEGF in PE placenta. However, it has to be noted that for ethical reasons, it is difficult to study gene expression in placentas prior to actual clinical diagnosis of PE.

The RAAS and angiotensin II AT-1 receptor auto-antibodies

In a recent review article Verdonk et al. presented a detailed account of the involvement of RAAS and Ang II AT-1 receptor auto-antibodies (AT-1AA) in the pathophysiology of pre-eclampsia. Readers are advised to refer to Verdonk et al. for details. They stated that in normal pregnancies, particularly in the early stages of gestation, there is an increase in maternal blood volume and a decrease in total resistance, and to counteract a fall in blood pressure, the RAAS is activated, resulting in sodium and water retention. However, in PE in contrast to normal pregnancy, the intravascular blood volume and cardiac output are reduced, while the total peripheral resistance is increased, and most components of the RAAS are downregulated.

These findings led them to conclude that in pre-eclampsia, the suppression of most components of the RAAS could lead to increased response to Ang II and AT-1AA. They reported that the exact role of the RAAS and AT-1AA systems in PE remains unanswered, suffice to state that the sensitivity of Ang II receptors to Ang II is increased, and angiotensinogen synthesis is stimulated by high circulatory oestrogen levels in the first 10 weeks of pregnancy.

High-molecular weight angiotensinogen levels were found to be about 25% higher than total angiotensinogen levels in PE, compared to 16% in normal pregnancy. However, it has been found that plasma renin activity, Ang II and aldosterone levels were decreased. At present, evidence of the exact role of the RAAS in PE is therefore lacking.

Circulating auto-antibodies to AT-1AA have been shown to increase after 20 weeks of gestation. Others have shown that AT-1AA was more predictive in late-onset than in early-onset PE. It is possible that Ang II, by activating the AT-1 receptors on human trophoblasts, could play a role in shallow trophoblast invasion of the spiral arteries through secretion of plasminogen activator inhibitor-1 (PAI-1). Similar findings for AT-1AA were noticed in in vitro studies using human mesangial cells, where it caused increased secretion of PAI-1 and IL-6, compared to IgG from normotensive patients. It was further speculated that the latter actions of AT-1AA could account for the renal damage seen in PE patients.

Xia and Kellems have presented a detailed review on the pathophysiological role of AT-1AA. They have shown that these auto-antibodies play a critical role in PE, and blockade of AT-1 receptors in animal models reversed the signs and symptoms of PE by reducing the circulatory levels of sFlt-1 and IL-6.

However, it remains to be shown conclusively that in human patients, AT-1AA plays an important role in the pathophysiology of PE, since most of the experiments were conducted in animal models, which may not represent what happens in PE. In addition, it has not been conclusively shown that in every pre-eclamptic woman, the levels of AT-1AA are raised.

Hydrogen sulphide

Hydrogen sulfide (H₂S) is a gaseous signalling molecule in humans and animals. It is produced in endothelial cells. It has vaso-relaxant properties and is involved in uterine contractility. Endogenously produced H₂S also has angiogenic and anti-inflammatory properties. In the latter case, H₂S acts at the endothelial-leukocyte interface. Chronic administration of H₂S was found to have hypotensive effects in a rat model and reduced infarct in ischaemia–reperfusion injury in experimental rats.

The production of H₂S requires one of two enzymes: cystathionine γ-lyase (CSE) or cystathionine β-synthase (CBS). Both these enzymes are localised in foetal endothelial cells of both the stem and chorionic villi, and the Hofbauer cells express CBS mRNA.

In early-onset but not late-onset PE, CBS mRNA expression was down-regulated. A recent study showed that mRNA expression of CSE was reduced in pre-eclamptic placental tissue and in women with SGA neonates, compared with normal pregnancy. The reduction in CSE expression was accompanied by reduction in the concentration of H₂S in the maternal circulation. In addition, it was found that trophoblasts and mesenchymal cells in the core of the chorionic villi were the sites for expression of CSE.

Inhibition of CSE by DL-propargylglycine (PAG) in pregnant mice resulted in hypertension and elevation in sFlt-1 and sEng levels in the circulation, and also caused placental abnormalities, while administration of GYY4137, which inhibits the action of PAG, reduced the levels of circulating sFlt-1 and sEng and restored foetal growth. This illustrates that H₂S is required for placental development.

Furthermore, it was also shown in in vitro studies that dysregulation of the CSE/H₂S pathway affected spiral artery remodelling and placental development. In addition, it was found that inhibition of CSE with PAG in placental explants taken from first-trimester pregnancies reduced PlGF production. Wang et al. are of the view that their findings imply that endogenous H₂S is required for placental development and foetal and maternal well-being. These findings perhaps show that H₂S plays a role in the pathogenesis and pathophysiology of PE. However, it is felt that plasma H₂S levels were overestimated in some of the above studies and may not reflect the true values.

Nulliparity has been suggested as a risk factor for PE. The risk of pre-eclampsia was 26% in nulliparous patients versus 17% in parous (RR and 95% CI: 1.5 (1.3–1.8)) subjects. The risk of PE is also increased with a history of abortion and changed parity. There seems to be a genetic component. Both mother and foetus contribute to the risk of PE, the contribution of the foetus being affected by paternal genes. An immune-based pathology is also proposed, whereby prolonged exposure to foetal antigens protects against PE in a subsequent pregnancy with the same father. Finally, a reason why PE is more common in nulliparous than multiparous women could be that in the latter, the uterine and spiral arteries develop a larger bore, which is easier for trophoblastic invasion.

"CARDIOVASCULAR JOURNAL OF AFRICA • Volume 27, No 2, March/April 2016"
The exact aetiology of PE remains elusive but much of the pathophysiology has been explained. The current theory is one of balance between angiogenic and anti-angiogenic factors. Measurement of circulatory angiogenic and anti-angiogenic proteins as biomarkers could possibly indicate placental dysfunction and differentiate PE from other disorders, such as gestational hypertension and chronic glomerulonephritis. In addition, biomarkers such as those stated above are reproducible, linked to the disease, and above all, are easy to interpret.

See Fig. 1 for some aspects of the pathophysiology of pre-eclampsia.

**Fig. 1. Aspects of pathophysiology of pre-eclampsia. VEGF: vascular endothelial growth factor; PIGF: placental growth factor; sFlt-1: soluble film-like tyrosine kinase.**

### Conclusion

The exact aetiology of PE remains elusive but much of the pathophysiology has been explained. The current theory is one of balance between angiogenic and anti-angiogenic factors. Measurement of circulatory angiogenic and anti-angiogenic proteins as biomarkers could possibly indicate placental dysfunction and differentiate PE from other disorders, such as gestational hypertension and chronic glomerulonephritis. In addition, biomarkers such as those stated above are reproducible, linked to the disease, and above all, are easy to interpret.

**Key messages**

- The exact aetiology of pre-eclampsia remains elusive.
- Much of the pathophysiology has been explained.
- Treatment remains empirical and cure is dependent on stabilisation of high blood pressure and other specific organ complications, followed by delivery of the foetus and placenta.

### References

1. American College of Obstetricians and Gynecologists. Task force on hypertension in pregnancy. Hypertension in Pregnancy 2013. http://www.acog.org/Resources_and_Publications/Task_Force_and_Work_Group_Reports/Hypertension_in_Pregnancy (accessed 2 June 2014).
2. O’Fairn-Byrne PP, Lash GE. Beyond pregnancy: modulation of trophoblast invasion and its consequences for fetal growth and long-term children’s health. J Reprod Immunol 2014; 104-105: 37-42.
3. Romero R, Chaiworapongsa T. Preeclampsia: a link between trophoblast dysregulation and an antiangiogenic state. J Clin Invest 2013; 123(7): 2775-2777.
4. Staff AC, Benton SJ, von Dadelszen P, et al. Redefining preeclampsia using placenta-derived biomarkers. Hypertension 2013; 61(5): 932-942.
5. von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclampsia. Hypertens Pregnancy 2003; 22(2): 143-148.
6. Huppertz B. Placental origins of preeclampsia: challenging the current hypothesis. Hypertension 2008; 52(4): 970-975.
7. Sohlberg S, Mulic-Lutvica A, Lindgren P, Ortiz-Nieto F, Wikstrom AK, Wikstrom J. Placental perfusion in normal pregnancy and early and late preeclampsia: a magnetic resonance imaging study. Placenta 2014; 35(3): 202-206.
8. Valensise H, Vasapollo B, Gagliardi G, Novelli GP. Early and late preeclampsia: two different maternal hemodynamic states in the latent phase of the disease. Hypertension 2008; 52(5): 873-880.
9. Zhong Y, Tuuli M, Odibo AO. First-trimester assessment of placenta function and the prediction of preeclampsia and intrauterine growth restriction. Prenat Diagn 2010; 30(4): 293-308.
10. Verdölk K, Visser W, Van Den Meiracker AH, Danser AH. The renin-angiotensin-aldosterone system in pre-eclampsia: the delicate balance between good and bad. Clin Sci (Lond) 2014; 126(8): 537-544.
11. Williams DJ, Vallance PJ, Neilh GH, Spencer JA, Imms FJ. Nitric oxide-mediated vasodilation in human pregnancy. Am J Physiol 1997; 272(2 Pt 2): H748-752.
12. Salas SP, Marshall G, Gutierrez BL, Rosso P. Time course of maternal plasma volume and hormonal changes in women with preeclampsia or fetal growth restriction. Hypertension 2006; 47(2): 203-208.
13. Zhou Y, McMaster M, Woo K, et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 2002; 160(4): 1405-1423.
14. Valenzuela FJ, Perez-Sepulveda A, Torres MJ, Correa P, Repetto GM, Illanes SE. Pathogenesis of preeclampsia: the genetic component. J Pregnancy 2012; Article ID: 632732: 8 pages. http://dx.doi.org/10.1155/2012/632732.
15. Brossens I, Pijnenborg R, Vercruysse L, Romero R. The “Great Obstetrical Syndromes” are associated with disorders of deep placentaion. Am J Obstet Gynecol 2011; 204(3): 193-201.
16. Foidart JM, Schaaps JP, Chantraine F, Munaut C, Lorquet S. Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia – a step forward but not the definitive answer. J Reprod Immunol 2009; 82(2): 106-111.
17. Whitely GS, Cartwright JE. Cellular and molecular regulation of spiral artery remodelling: lessons from the cardiovascular field. Placenta 2010; 31(6): 465-474.
18. Moffett A, Colucci F. Uterine NK cells: active regulators at the maternal-fetal interface. J Clin Invest 2014; 124(5): 1872-1879.
19. Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999; 180(2 Pt 1): 499-506.
20. Sargent IL, Germain SJ, Sacks GP, Kumar S, Redman CW. Trophoblast depar- tation and the maternal inflammatory response in pre-eclampsia. J Reprod Immunol 2003; 59(2): 153–160.

21. Germain SJ, Sacks GP, Sooranna SR, Sargent IL, Redman CW. Systemic inflammatory priming in normal pregnancy and preeclampsia: the role of circulating syncytiotrophoblast microparticles. J Immunol 2007; 178(9): 5949–5956.

22. Tannetta DS, Dragovic RA, Gardner C, Redman CW, Sargent IL. Characterisation of syncytiotrophoblast vesicles in normal pregnancy and pre-eclampsia: expression of Fln-1 and endoglin. Placenta 2013; 8(2): e56754.

23. Staff AC, Johnsen GM, Dechend R, Redman CW. Preeclampsia and uteroplacental acute atherosclerosis: immune and inflammatory factors. J Reprod Immunol 2014; 101–102: 120–126.

24. Redman CW, Sargent IL, Staff AC. IFPA Senior Award lecture: making sense of pre-eclampsia – two placental causes of preeclampsia? Placenta 2014; 35(Suppl): S20–25.

25. Founds SA, Conley YP, Lyons-Weiler JF, Jeyabalan A, Hogge WA, Conrad KP. Altered global gene expression in first trimester placentas of women destined to develop preeclampsia. Placenta 2009; 30(1): 15–24.

26. Pollheimer J, Fock V, Knofler M. Review: the ADAM metalloproteinases – novel regulators of trophoblast invasion? Placenta 2014; 35(Suppl): S57–63.

27. Ramases SV, Mackrath I, Gathiram P, Moodley J. Sildenafil citrate improves fetal outcomes in pregnant, L-NAMe treated, Sprague-Dawley rats. Eur J Obstet Gynecol Reprod Biol 2010; 149(1): 22–26.

28. Ramases SV, Mackrath I, Gathiram P, Moodley J. Sildenafil citrate decreases sFlt-1 and sEng in pregnant L-NAMe treated Sprague-Dawley rats. Eur J Obstet Gynecol Reprod Biol 2011; 157(2): 136–140.

29. Bajnath S, Soobryan N, Mackrath I, Gathiram P, Moodley J. The optimization of a chronic nitric oxide synthase (NOS) inhibition model of pre-eclampsia by physiological changes. Eur J Obstet Gynecol Reprod Biol 2014; 182: 71–75.

30. Redman CW, Sargent IL. Latest advances in understanding preeclamp- sia. Science 2005; 308(5728): 1592–1594.

31. Hung TH, Burton GJ. Hypoxia and reoxygenation: a possible mecha- nism for placental oxidative stress in preeclampsia. Taiwan J Obstet Gynecol 2006; 45(3): 189–200.

32. Yung HW, Atkinson D, Lyons-Weiler JF, Jeyabalan A, Hogge WA, Conrad KP. Altered global gene expression in first trimester placentas of women destined to develop preeclampsia. Placenta 2009; 30(1): 15–24.

33. Pollheimer J, Fock V, Knofler M. Review: the ADAM metalloprotein- enases – novel regulators of trophoblast invasion? Placenta 2014; 35(Suppl): S57–63.

34. Sargent IL, Borzychowski AM, Redman CW. Immunoregulation in normal pregnancy and early-onset pre-eclampsia. J Matern Fetal Neonatal Med 2014; 27(11): 234–240.

35. Sargent IL, Borzychowski AM, Redman CW. Immunoregulation in normal pregnancy and pre-eclampsia: an overview. Reprod Immunol 2006; 13(5): 680–686.

36. Hawfield A, Freedman BI. Pre-eclampsia: the pivotal role of the placentas in its pathophysiology and markers for early detection. Therap Adv Cardiovasc Dis 2009; 3(1): 65–73.

37. Uzan J, Carbonnel M, Piconne O, Asmar R, Ayoubi JM. Pre-eclampsia: pathophysiology, diagnosis, and management. Vasc Health Risk Mgmt 2011; 7: 467–474.

38. Alon T, Hemo I, Itin A, Pe’er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nature Med 1995; 1(10): 1024–1028.

39. Taylor RN, Grimwood J, Taylor RS, McMaster MT, Fisher SJ, North RA. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 2003; 188(1): 177–182.

40. Jones RL, Stoikos C, Findlay JK, Salamonsen LA. TGF-beta super- family expression and actions in the endometrium and placenta. Reproduction 2006; 132(2): 217–223.

41. Fu G, Ye G, Nadeem L, et al. MicroRNA-376c impairs transforming growth factor-beta and nodal signaling to promote trophoblast cell proliferation and invasion. Hypertension 2013; 61(4): 864–872.

42. Bldolah Y, Karumanchi SA, Sachs BP. Recent advances in understanding of preeclampsia. Croat Med J 2005; 46(5): 728–736.

43. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13(1): 9–22.

44. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nature Med 2006; 12(6): 642–649.

45. Bell MJ, Conley YP. A systematic review of endoglin gene expression in preeclampsia. Biol Res Nurs 2013; 13(2): 129–136.

46. Bldolah Y, Sukhatme VP, Karumanchi SA. Angiogenic imbalance in the pathophysiology of preeclampsia: newer insights. Seminars Nephrol 2004; 24(6): 548–556.

47. Maynard SE, Karumanchi SA. Angiogenic factors and preeclampsia. Seminars Nephrol 2011; 31(1): 33–46.

48. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. New Engl J Med 2004; 350(7): 672–683.

49. Romero R, Nien JK, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008; 21(1): 9–23.

50. Maynard SE, Min JY, Merchant J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111(5): 649–658.

51. Govender N, Naicker T, Moodley J. Maternal imbalance between pro-angiogenic and anti-angiogenic factors in HIV-infected women with pre-eclampsia. Cardiovasc J Afr 2013; 24(5): 174–179.

52. Govender L, Mackrath I, Gathiram P, Moodley J. The role of angiogenic, anti-angiogenic and vasoactive factors in pre-eclamptic African women: early- versus late-onset pre-eclampsia. Cardiovasc J Afr 2012; 23(3): 153–159.

53. Erez O, Romero R, Espinoza J, et al. The change in concentrations of angiogenic and antiangiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med 2008; 21(5): 279–287.

54. Vatten LJ, Asvold BO, Eskild A. Angiogenic factors in maternal circulation and preeclampsia with or without fetal growth restriction. Acta Obstet Gynecol Scand 2012; 91(12): 1388–1394.

55. Chaiworapongsa T, Romero R, Kim YM, et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 2005; 17(1): 3–18.

56. Thadhani R, Kisner T, Hagemann H, et al. Pilot study of extracor- poreal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 2011; 124(8): 940–950.

57. Saito S, Shiozaki A, Nakashima A, Sakai M, Sasaki Y. The role of the immune system in preeclampsia. Molec Aspects Med 2007; 28(2): 192–209.

58. Szarka A, Rigo J, Jr, Lazar L, Beko G, Molvarec A. Circulating...
cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array. *BMC Immunol* 2010; 11: 59.

59. Saito S, Sakai M. Th1/Th2 balance in preeclampsia. *J Reprod Immunol* 2003; 59(2): 161–173.

60. Kumar A, Begum N, Prasad S, Agarwal S, Sharma S. IL-10, TNF-alpha 
& IFN-gamma: potential early biomarkers for preeclampsia. *Cell Immunol* 2013; 283(1–2): 70–74.

61. Peracoli JC, Bannwart-Castro CF, Romao M, et al. High levels of heat shock protein 70 are associated with pro-inflammatory cytokines and may differentiate early- from late-onset preeclampsia. *J Reprod Immunol* 2013; 100(2): 129–134.

62. Lau SY, Guild SJ, Barrett CJ, et al. Tumor necrosis factor-alpha, interleukin-6, and interleukin-10 levels are altered in preeclampsia: a systematic review and meta-analysis. *Am J Reprod Immunol* 2013; 70(5): 412–427.

63. Ajith A. The role of peripheral natural killer cells in immunocompromised pre-eclamptic and normotensive pregnant South Africans. PhD dissertation, University of KwaZulu-Natal, Durban, 2016.

64. Pinheiro MB, Martins-Filho OA, Mota AP, et al. Severe preeclampsia goes along with a cytokine network disturbance towards a systemic inflammatory state. *Cytokine* 2013; 62(1): 165–173.

65. Laresgoiti-Servitje E. A leading role for the immune system in the pathophysiology of preeclampsia. *J Leukoc Biol* 2009; 86(2): 247–257.

66. Caniggia I, Winter JL, Lye SJ, Post M. Oxygen and placental development during the first trimester: implications for the pathophysiology of pre-eclampsia. *Placenta* 2000; 21 (Suppl A): S25–30.

67. Ymon Y, Nevo O, Xu J, et al. Severe intrauterine growth restriction pregnancies have increased placental endoglin levels: hypoxic regulation via transforming growth factor-beta 3. *Am J Pathol* 2008; 172(1): 77–85.

68. Redman CW, Sargent JL. Placental stress and pre-eclampsia: a revised view. *Placenta* 2009; 30 (Suppl A): S38–42.

69. Tewksbury DA, Dart RA. High molecular weight angiotensinogen levels in hypertensive pregnant women. *Hypertension* 1982; 4(5): 729–734.

70. Brown MA, Wang J, Whitworth JA. The renin-angiotensin-aldosterone system in pre-eclampsia. *Clin Exp Hypertens* 1997; 19(5–6): 713–726.

71. Wenzel K, Rajakumar A, Haase H, et al. Angiotensin II type 1 receptor antibodies and increased angiotensin II sensitivity in pregnant rats. *Hypertension* 2011; 58(1): 77–84.

72. Herse F, Verloren S, Wenzel K, et al. Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study. *Hypertension* 2009; 53(2): 393–398.

73. Bobst SM, Day MC, Gilstrap LC, 3rd, Xia Y, Kellems RE. Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-1 secretion. *Am J Hypertens* 2005; 18(3): 330–336.

74. Xia Y, Kellems RE. Angiotensin receptor agonistic autoantibodies and hypertension: preeclampsia and beyond. *Circ Res* 2013; 113(1): 78–87.

75. Papapetropoulos A, Pyrochou A, Altaany Z, et al. Hydrogen sulfide is an endogenous stimulator of angiogenesis. *Proc Natl Acad Sci USA* 2009; 106(51): 21972–21977.

76. Zhao W, Zhang J, Lu Y, Wang R. The vasorelaxant effect of H(2)S as a novel endogenous gaseous K(ATP) channel opener. *EMBO J* 2001; 20(21): 6008–6016.

77. You XJ, Xu C, Lu QJ, et al. Expression of cystathionine beta-synthase and cystathionine gamma-lyase in human pregnant myometrium and their roles in the control of uterine contractility. *PLoS One* 2011; 6(8): 123788.

78. Zanardo RC, Brancalone V, Distrettini E, Fiorucci S, Cirino G, Wallace JL. Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. *FASEB J* 2006; 20(12): 2118–2120.

79. Zhuo Y, Chen PF, Zhang AZ, Zhong H, Chen CQ, Zhu YZ. Cardioprotective effect of hydrogen sulfide in ischemic reperfusion experimental rats and its influence on expression of survivin gene. *Biol Pharm Bull* 2009; 32(8): 1406–1410.

80. Holwerda KM, Bos EM, Rajakumar A, et al. Hydrogen sulfide producing enzymes in pregnancy and preeclampsia. *Placenta* 2012; 33(6): 518–521.

81. Wang X, Ahmad S, Cai M, et al. Dysregulation of hydrogen sulfide producing enzyme cystathionine gamma-lyase contributes to maternal hypertension and placental abnormalities in preeclampsia. *Circulation* 2013; 127(25): 2514–2522.

82. Wang X, Ahmad S, Cai M, et al. Response to letter regarding article, ‘Dysregulation of hydrogen sulfide (H,S) producing enzyme cystathionine gamma-lyase (CSE) contributes to maternal hypertension and placental abnormalities in preeclampsia.’ *Circulation* 2014; 129(22): e517–518.

83. Zhou Y, Gormley MJ, Hunkapiller NM, et al. Reversal of gene dysregulation in cultured cytотrophoblasts reveals possible causes of preeclamp-sia. *J Clin Invest* 2013; 123(7): 2862–2872.

84. Basso O. Re: Abortion, changed paternity, and risk of preeclampsia in nulliparous women. *Am J Epidemiol* 2003; 158(8): 825.

85. Shamsi U, Saleem S, Nishter N. Epidemiology and risk factors of preeclampsia in nulliparous women'. *Al Ameen J Med Sci* 2013; 6(4): 292–300.